Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

Supratentorial Central Neurocytomas in Children Homepage

This page was last updated on June 9th, 2022


Sandip Chatterjee, M.D.

Section Editor

Kristian Aquilina, M.D.

Editor in Chief

Rick Abbott, M.D.


Central neurocytomas, classified as “mixed neuronal and glial” tumors, present in children and young adults as well-circumscribed intraventricular masses that are often amenable to total surgical removal.

Key Points

  • Benign: These tumors are essentially benign, but there is an “atypical” variant that is more aggressive in behavior.
  • Intraventricular: Generally, these tumors are intraventricular in location, occurring mostly in the frontal horn. Rarely, they may be “extraventricular.”
  • Gross total resection preferred: Given their intraventricular location, total surgical resection is usually possible and is the treatment of choice.
  • Radiation for unresectable tumor and atypical variant: For residual tumor and “atypical” cases, adjuvant therapy is indicated in the form of radiotherapy.  Both conventional and stereotactic radiotherapy have been used with equal success.

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.